MS
Morgan Stanley
MS has slightly lower modeled downside risk, despite its lower overall score.
RNST
Renasant Corporation
RNST has a slight edge over MS overall, supported by stronger fundamentals and stronger valuation.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
RNST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
RNST's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like RNST.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
RNST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $36.94 | -7.4% |
| Current | 11x | $39.91 | — |
| Forward | 11x | $39.91 | — |
| Fair | 12x | $43.25 | +8.4% |
| Expensive | 17x | $60.97 | +53% |
Historical ranges are pointers, not guarantees.
RNST has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
RNST Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for RNST, with profitability improving.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over RNST on earnings, with more consistent year-over-year improvement.
RNST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.73 | +6.1% |
| Q3 2026 | $3.52 | +77% |
| Q2 2026 | $3.29 | +30% |
| Q1 2026 | $2.36 | -27% |
| Q4 2025 | $2.07 | -37% |
| Q3 2025 | $1.99 | -35% |
| Q2 2025 | $2.54 | -3.1% |
| Q1 2025 | $3.22 | +32% |
| Q4 2024 | $3.27 | +28% |
RNST earned $3.52 per share over the past year, up 77% from the year before.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
RNST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $273M | +1.3% |
| Q2 2026 | $273.9M | +2.5% |
| Q1 2026 | $273.8M | +60% |
| Q4 2025 | $278.5M | +67% |
| Q3 2025 | $269.5M | +22% |
| Q2 2025 | $267.2M | +63% |
| Q1 2025 | $170.7M | +3.6% |
| Q4 2024 | $167.1M | +14% |
RNST has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +8.5 points |
| Q2 2026 | 40% | +39 points |
| Q1 2026 | 40% | +9.9 points |
| Q4 2025 | 35% | +5 points |
| Q3 2025 | 28% | -16 points |
| Q2 2025 | 1% | -29 points |
| Q1 2025 | 30% | +0.5 points |
| Q4 2024 | 30% | +8 points |
RNST has the edge over MS on profitability, with a higher operating margin.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
RNST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $161.9M | +35% |
| Q2 2026 | $76.4M | +$163.9M |
| Q1 2026 | $93.7M | -7.5% |
| Q4 2025 | $103.8M | +17% |
| Q3 2025 | $120.1M | +578% |
| Q2 2025 | -$87.5M | -$34.9M |
| Q1 2025 | $101.3M | +64% |
| Q4 2024 | $88.9M | -6.7% |
RNST has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
RNST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -663K shares |
| 1 year | -3.9% | -3.7M shares |
| 3 years | +62% | +35M shares |
| 5 years | +62% | +35.1M shares |
| Available history | +57% | +33.3M shares |
RNST has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $43.1M |
| Q2 2026 | $60.5M |
| Q1 2026 | $75.8M |
| Q4 2022 | — |
| Q4 2021 | $1,000 |
| Q3 2021 | $21.3M |
| Q2 2021 | — |
| Q1 2021 | — |
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
RNST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | -1.4x | Net Cash |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | -1.8x | Net Cash |
| Q1 2025 | -2.0x | Net Cash |
| Q4 2024 | -2.0x | Net Cash |
RNST has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
RNST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 34.4 | Neutral |
RNST's weekly RSI is 47 (neutral) and its Stochastic is 34 (neutral).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
RNST PE vs Financial Services Sector
| Metric | RNST | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 13% below |
| PE % | 31 | 63 | 32 pts below |
RNST has the edge over MS on valuation relative to its sector.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
RNST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.0 | 0.2% below |
| 20 week MA | $41.4 | 3.6% below |
| 50 week MA | $39.7 | 0.4% above |
| 100 week MA | $37.7 | 6% above |
| 200 week MA | $34.3 | 16% above |
RNST has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 16% above its 200-week average.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.
RNST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.6 | $33.3 | -6.6% |
| 2021 | $33.3 | $37.6 | +13% |
| 2022 | $37.6 | $38.2 | +1.8% |
| 2023 | $38.2 | $33.7 | -12% |
| 2024 | $33.7 | $35.8 | +6.3% |
| 2025 | $35.8 | $36.2 | +1% |
| 2026 YTD | $36.2 | $39.9 | +10% |
RNST has the edge over MS on returns for 2026, with the stronger performance.